Lilly Zyprexa
Executive Summary
Company has submitted data on treatment of behavior and psychiatric symptoms of Alzheimer's to FDA for labeling enhancement of olanzapine. A 206-patient, six-week study presented at the American College of Neuropsychopharmacology annual meeting in San Juan, Puerto Rico Dec. 15 found that 5 mg and 10 mg daily doses were associated with a statistically significant 65.5% and 57.1% improvement, respectively, in agitation/aggression, delusions and hallucinations associated with Alzheimer's disease, compared to 35.6% improvement for placebo